Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nuvalent, Inc. (NUVL)
USD123.96
+0.00 (+0.00%)
US NASDAQ Healthcare Biotechnology
Address
One Broadway 2142
Cambridge, MA, US
Cambridge, MA, US
CEO
James R. Porter
Website
nuvalent.com
IPO
2021-07-29
CIK 1861560 ISIN US6707031075
Description
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD123.96
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
1.15
Float Shares
48.67M
Free Float %
66.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.92% | -1.51% | -0.19% | +1.19% | +5.68% | +1.94% | +39.26% | +160.25% | +446.88% | +446.88% | +446.88% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (14 ratings, all time)
Buy
Price Targets & DCF
Current price
123.96
Low
140.00
+12.9%
Consensus
149.00
+20.2%
Median
150.50
+21.4%
High
155.00
+25.0%
DCF (Unlevered)
3.22
-97.4%
DCF (Levered)
3.60
-97.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 15 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 12 |
132.83
+7.2%
|
| All Time | 20 |
124.50
+0.4%
|
Quality scores
Altman Z-Score
28.13
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-48.9% Q1'26: -17.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +422.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+9.5% Q1'26: +9.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 12 Rev. Ana. 8 EPS Ana. |
Dec 2027 13 Rev. Ana. 12 EPS Ana. |
Dec 2028 13 Rev. Ana. 10 EPS Ana. |
Dec 2029 12 Rev. Ana. 4 EPS Ana. |
Dec 2030 6 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 6.25M (-100.0%)
|
13.13M
571.0K – 31.62M
+110.1% YoY
|
191.87M
104.71M – 257.13M
+1,361.0% YoY
|
508.38M
503.75M – 513.00M
+165.0% YoY
|
908.51M
354.83M – 1.57B
+78.7% YoY
|
1.22B
475.76M – 2.11B
+34.1% YoY
|
| EBITDA |
—
|
-10.49M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-280.37M
|
-424.79M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-260.76M
est: -257.01M (-1.5%)
|
-425.38M
est: -416.53M (-2.1%)
|
-453.38M
-533.81M – -323.11M
-8.8% YoY
|
-362.25M
-483.78M – -162.84M
+20.1% YoY
|
-122.17M
-438.69M – 289.09M
+66.3% YoY
|
219.18M
45.53M – 427.82M
+279.4% YoY
|
391.56M
81.34M – 764.28M
+78.6% YoY
|
| SGA |
62.59M
|
107.34M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-3.93
est: -3.91 (-0.5%)
|
-5.85
est: -5.72 (-2.4%)
|
-5.63
-7.34 – -4.45
+1.5% YoY
|
-4.28
-6.66 – -2.24
+23.9% YoY
|
-1.35
-6.04 – 3.98
+68.4% YoY
|
3.02
0.63 – 5.89
+322.9% YoY
|
5.39
1.12 – 10.51
+78.6% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-21 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
58
Total invested
197.45M
Insider transactions (90d)
4
Beneficial owners (>5%)
22
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Deerfield Management Company, L.P. | 25.47M | 39.24% | — | 25.47M | — | — | PN | Delaware | 2022-11-14 | ↗ |
| 2 | James E. Flynn | 25.47M | 39.24% | — | 25.47M | — | — | IN | Delaware | 2022-11-14 | ↗ |
| 3 | Deerfield Healthcare Innovations Fund, L.P. | 12.39M | 18.96% | — | 12.39M | — | — | PN | Delaware | 2022-11-14 | ↗ |
| 4 | Deerfield Mgmt HIF, L.P. | 12.39M | 18.96% | — | 12.39M | — | — | PN | Delaware | 2022-11-14 | ↗ |
| 5 | Deerfield Mgmt IV, L.P. | 12.39M | 18.96% | — | 12.39M | — | — | PN | Delaware | 2022-11-14 | ↗ |
| 6 | Deerfield Private Design Fund IV, L.P. | 12.39M | 18.96% | — | 12.39M | — | — | PN | Delaware | 2022-11-14 | ↗ |
| 7 | Abigail P. Johnson | 4.70M | 11.42% | — | — | 4.70M | — | IN | Delaware | 2021-08-10 | ↗ |
| 8 | FMR LLC | 4.70M | 11.42% | 983.5K | — | 4.70M | — | HC | Delaware | 2021-08-10 | ↗ |
| 9 | (1) BlackRock, Inc. | 3.62M | 5.60% | 3.54M | — | 3.62M | — | HC | Delaware | 2024-11-08 | ↗ |
| 10 | The Vanguard Group - 23-1945930 | 3.34M | 5.72% | — | — | — | 75.3K | IA | Pennsylvania | 2024-02-13 | ↗ |
| 11 | Joseph Edelman | 2.92M | 5.10% | — | 2.92M | — | 2.92M | IN | Delaware | 2024-01-02 | ↗ |
| 12 | Perceptive Advisors LLC | 2.92M | 5.10% | — | 2.92M | — | 2.92M | IA | Delaware | 2024-01-02 | ↗ |
| 13 | Perceptive Life Sciences Master Fund, Ltd. | 2.92M | 5.10% | — | 2.92M | — | 2.92M | CO | Delaware | 2024-01-02 | ↗ |
| 14 | Fairmount Funds Management LLC | 2.61M | 5.13% | — | 2.61M | — | — | IA | Delaware | 2022-11-09 | ↗ |
| 15 | Peter Harwin | 2.61M | 5.13% | — | 2.61M | — | — | HC, IN | Delaware | 2022-11-09 | ↗ |
| 16 | Tomas Kiselak | 2.61M | 5.13% | — | 2.61M | — | — | HC, IN | Delaware | 2022-11-09 | ↗ |
| 17 | Fairmount Healthcare Fund II L.P. | 2.52M | 4.97% | — | 2.52M | — | — | PN | Delaware | 2022-11-09 | ↗ |
| 18 | Bain Capital Life Sciences Fund II, L.P. | 2.40M | 5.60% | — | 2.40M | — | 2.40M | PN | — | 2021-08-04 | ↗ |
| 19 | BCLS II Investco, LP | 735.0K | 1.70% | — | 735.0K | — | 735.0K | PN | — | 2021-08-04 | ↗ |
| 20 | Deerfield Mgmt, L.P. | 650.0K | 1.27% | — | 650.0K | — | — | PN | Delaware | 2022-11-14 | ↗ |
| 21 | Deerfield Partners, L.P. | 650.0K | 1.27% | — | 650.0K | — | — | PN | Delaware | 2022-11-14 | ↗ |
| 22 | BCIP Life Sciences Associates, LP | 292.4K | 0.70% | — | 292.4K | — | 292.4K | PN | — | 2021-08-04 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
58
-181 vs prev Q
New positions
8
Closed positions
186
Increased
29
Reduced
15
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 269.0K +269.0K (+100.0%) | 27.06B +27.1B (+100.0%) | 0.37% +0.373 pp | 3.67% +3.668 pp | USD100.59 +0.0% | 1 qtrs NEW |
| 2 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 17.25M -742.6K (-4.1%) | 1.74B +179.2M (+11.5%) | 23.91% -1.133 pp | 22.16% -1.593 pp | USD22.79 +341.4% | 18 qtrs — |
| 3 | FMR LLC | 10.85M +839.6K (+8.4%) | 1.09B +225.7M (+26.1%) | 15.04% +1.106 pp | 0.06% +0.011 pp | USD42.74 +135.4% | 18 qtrs — |
| 4 | PARADIGM BIOCAPITAL ADVISORS LP | 5.27M +— (+0.0%) | 530.05M +74.4M (+16.3%) | 7.30% -0.031 pp | 13.53% +0.569 pp | USD67.32 +49.4% | 11 qtrs — |
| 5 | VANGUARD GROUP INC | 5.24M +639.3K (+13.9%) | 527.52M +129.3M (+32.5%) | 7.27% +0.860 pp | 0.01% +0.002 pp | USD58.92 +70.7% | 18 qtrs — |
| 6 | BLACKROCK, INC. | 4.81M +719.5K (+17.6%) | 483.36M +130.0M (+36.8%) | 6.66% +0.974 pp | 0.01% +0.002 pp | USD99.20 +1.4% | 6 qtrs — |
| 7 | WELLINGTON MANAGEMENT GROUP LLP | 2.46M +161.0K (+7.0%) | 247.63M +48.7M (+24.5%) | 3.41% +0.210 pp | 0.04% +0.009 pp | USD72.67 +38.4% | 18 qtrs — |
| 8 | JPMORGAN CHASE & CO | 2.21M +531.2K (+31.7%) | 221.83M +77.1M (+53.2%) | 3.06% +0.727 pp | 0.01% +0.005 pp | USD83.71 +20.2% | 18 qtrs — |
| 9 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.15M +336.5K (+18.6%) | 215.96M +59.4M (+37.9%) | 2.98% +0.456 pp | 0.02% +0.007 pp | USD72.92 +37.9% | 13 qtrs — |
| 10 | RA CAPITAL MANAGEMENT, L.P. | 1.88M +633.6K (+50.8%) | 189.11M +81.3M (+75.4%) | 2.61% +0.871 pp | 1.94% +0.609 pp | USD91.24 +10.2% | 2 qtrs — |
| 11 | STATE STREET CORP | 1.86M +289.9K (+18.4%) | 187.57M +51.4M (+37.7%) | 2.58% +0.393 pp | 0.01% +0.002 pp | USD57.89 +73.8% | 18 qtrs — |
| 12 | PERCEPTIVE ADVISORS LLC | 1.67M +102.8K (+6.6%) | 167.49M +32.4M (+24.0%) | 2.31% +0.133 pp | 2.99% -0.916 pp | USD50.35 +99.8% | 18 qtrs — |
| 13 | POLAR CAPITAL HOLDINGS PLC | 1.54M +514.6K (+50.3%) | 154.59M +66.2M (+74.9%) | 2.13% +0.707 pp | 0.60% +0.172 pp | USD87.41 +15.1% | 7 qtrs — |
| 14 | JANUS HENDERSON GROUP PLC | 1.50M -689.1K (-31.5%) | 150.82M -38.5M (-20.3%) | 2.08% -0.968 pp | 0.07% -0.019 pp | USD74.87 +34.4% | 18 qtrs — |
| 15 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 1.32M +298.7K (+29.3%) | 132.78M +44.5M (+50.3%) | 1.83% +0.408 pp | 0.08% +0.030 pp | USD80.08 +25.6% | 4 qtrs — |
| 16 | GEODE CAPITAL MANAGEMENT, LLC | 1.24M +144.2K (+13.2%) | 124.58M +30.0M (+31.7%) | 1.72% +0.194 pp | 0.01% +0.002 pp | USD58.46 +72.1% | 18 qtrs — |
| 17 | BELLEVUE GROUP AG | 1.04M +1.0M (+100.0%) | 104.36M +104.4M (+100.0%) | 1.44% +1.438 pp | 1.98% +1.978 pp | USD100.59 +0.0% | 1 qtrs NEW |
| 18 | BRAIDWELL LP | 821.4K -191.6K (-18.9%) | 82.63M -5.0M (-5.7%) | 1.14% -0.271 pp | 2.64% +0.043 pp | USD73.96 +36.0% | 5 qtrs — |
| 19 | ALLIANCEBERNSTEIN L.P. | 785.4K +735.5K (+1,471.9%) | 79.01M +74.7M (+1,728.4%) | 1.09% +1.019 pp | 0.02% +0.024 pp | USD98.08 +2.6% | 14 qtrs — |
| 20 | FAIRMOUNT FUNDS MANAGEMENT LLC | 727.6K +— (+0.0%) | 73.19M +10.3M (+16.3%) | 1.01% -0.004 pp | 5.57% -0.091 pp | USD21.60 +365.7% | 18 qtrs — |
| 21 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 643.0K +68.5K (+11.9%) | 64.68M +15.0M (+30.2%) | 0.89% +0.092 pp | 0.10% +0.019 pp | USD86.18 +16.7% | 6 qtrs — |
| 22 | WOODLINE PARTNERS LP | 610.5K -459.1K (-42.9%) | 61.41M -31.1M (-33.6%) | 0.85% -0.643 pp | 0.24% -0.197 pp | USD81.86 +22.9% | 14 qtrs — |
| 23 | GOLDMAN SACHS GROUP INC | 594.5K +150.0K (+33.8%) | 59.80M +21.4M (+55.6%) | 0.82% +0.205 pp | 0.01% +0.003 pp | USD76.79 +31.0% | 17 qtrs — |
| 24 | NORGES BANK | 574.2K +574.2K (+100.0%) | 57.76M +57.8M (+100.0%) | 0.80% +0.796 pp | 0.01% +0.006 pp | USD100.59 +0.0% | 1 qtrs NEW |
| 25 | AMERIPRISE FINANCIAL INC | 564.3K +37.2K (+7.1%) | 56.76M +11.2M (+24.5%) | 0.78% +0.049 pp | 0.01% +0.002 pp | USD81.90 +22.8% | 6 qtrs — |
| 26 | COMMODORE CAPITAL LP | 550.0K -850.0K (-60.7%) | 55.32M -65.7M (-54.3%) | 0.76% -1.186 pp | 3.68% -2.228 pp | USD63.30 +58.9% | 13 qtrs — |
| 27 | DRIEHAUS CAPITAL MANAGEMENT LLC | 483.5K +266.9K (+123.3%) | 48.64M +29.9M (+159.7%) | 0.67% +0.369 pp | 0.33% +0.196 pp | USD72.90 +38.0% | 18 qtrs — |
| 28 | HOOD RIVER CAPITAL MANAGEMENT LLC | 475.4K +475.4K (+100.0%) | 47.82M +47.8M (+100.0%) | 0.66% +0.659 pp | 0.52% +0.524 pp | USD100.59 +0.0% | 1 qtrs NEW |
| 29 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 453.3K +48.8K (+12.1%) | 45.60M +10.6M (+30.3%) | 0.63% +0.065 pp | 0.01% +0.002 pp | USD66.69 +50.8% | 18 qtrs — |
| 30 | INVESCO LTD. | 439.3K +405.5K (+1,201.4%) | 44.19M +41.3M (+1,413.7%) | 0.61% +0.562 pp | 0.01% +0.006 pp | USD100.28 +0.3% | 14 qtrs — |
| 31 | FRANKLIN RESOURCES INC | 411.4K +251.2K (+156.9%) | 41.38M +27.5M (+198.8%) | 0.57% +0.347 pp | 0.01% +0.007 pp | USD81.68 +23.2% | 11 qtrs — |
| 32 | NORTHERN TRUST CORP | 410.5K +29.0K (+7.6%) | 41.29M +8.3M (+25.1%) | 0.57% +0.038 pp | 0.01% +0.001 pp | USD55.29 +81.9% | 18 qtrs — |
| 33 | UBS GROUP AG | 399.1K +185.9K (+87.2%) | 40.14M +21.7M (+117.8%) | 0.55% +0.257 pp | 0.01% +0.004 pp | USD87.43 +15.1% | 13 qtrs — |
| 34 | AMERICAN CENTURY COMPANIES INC | 374.2K +11.3K (+3.1%) | 37.64M +6.3M (+19.9%) | 0.52% +0.014 pp | 0.02% +0.003 pp | USD76.66 +31.2% | 5 qtrs — |
| 35 | FIRST TURN MANAGEMENT, LLC | 368.7K -26.1K (-6.6%) | 37.09M +2.9M (+8.6%) | 0.51% -0.038 pp | 4.24% -0.888 pp | USD82.40 +22.1% | 9 qtrs — |
| 36 | CANDRIAM S.C.A. | 358.0K +28.3K (+8.6%) | 36.01M +7.5M (+26.3%) | 0.50% +0.037 pp | 0.18% +0.030 pp | USD56.70 +77.4% | 13 qtrs — |
| 37 | PICTET ASSET MANAGEMENT HOLDING SA | 355.7K -28.9K (-7.5%) | 35.78M +2.5M (+7.6%) | 0.49% -0.042 pp | 0.03% +0.003 pp | USD77.16 +30.4% | 9 qtrs — |
| 38 | AFFINITY ASSET ADVISORS, LLC | 322.6K -61.8K (-16.1%) | 32.45M -790.7K (-2.4%) | 0.45% -0.088 pp | 1.85% -1.047 pp | USD77.82 +29.3% | 10 qtrs — |
| 39 | SILVERARC CAPITAL MANAGEMENT, LLC | 311.4K -60.9K (-16.3%) | 31.33M -869.8K (-2.7%) | 0.43% -0.087 pp | 4.35% +0.009 pp | USD79.05 +27.2% | 14 qtrs — |
| 40 | TRI LOCUM PARTNERS LP | 307.4K +307.4K (+100.0%) | 30.92M +30.9M (+100.0%) | 0.43% +0.426 pp | 4.01% +4.015 pp | USD100.59 +0.0% | 4 qtrs — |
| 41 | ARROWMARK COLORADO HOLDINGS LLC | 296.0K -66.6K (-18.4%) | 29.78M -1.6M (-5.0%) | 0.41% -0.094 pp | 0.66% +0.073 pp | USD69.73 +44.3% | 13 qtrs — |
| 42 | LORD, ABBETT & CO. LLC | 281.2K +281.2K (+100.0%) | 28.29M +28.3M (+100.0%) | 0.39% +0.390 pp | 0.09% +0.087 pp | USD100.59 +0.0% | 1 qtrs NEW |
| 43 | FRONTIER CAPITAL MANAGEMENT CO LLC | 270.5K +270.5K (+100.0%) | 27.21M +27.2M (+100.0%) | 0.37% +0.375 pp | 0.29% +0.289 pp | USD100.59 +0.0% | 1 qtrs NEW |
| 44 | MORGAN STANLEY | 267.4K -7.7K (-2.8%) | 26.90M +3.1M (+13.1%) | 0.37% -0.012 pp | 0.00% +0.000 pp | USD71.32 +41.0% | 18 qtrs — |
| 45 | CITADEL ADVISORS LLC | 195.2K +164.9K (+545.7%) | 19.63M +17.0M (+651.0%) | 0.27% +0.228 pp | 0.00% +0.003 pp | USD99.12 +1.5% | 16 qtrs — |
| 46 | BANK OF AMERICA CORP /DE/ | 180.4K +19.2K (+11.9%) | 18.14M +4.2M (+30.2%) | 0.25% +0.026 pp | 0.00% +0.000 pp | USD71.35 +41.0% | 18 qtrs — |
| 47 | BNP PARIBAS ARBITRAGE, SNC | 174.1K +36.1K (+26.2%) | 17.51M +5.6M (+46.8%) | 0.24% +0.049 pp | 0.01% +0.002 pp | USD80.39 +25.1% | 5 qtrs — |
| 48 | VOYA INVESTMENT MANAGEMENT LLC | 172.5K +37.8K (+28.0%) | 17.35M +5.7M (+48.9%) | 0.24% +0.052 pp | 0.02% +0.006 pp | USD80.90 +24.3% | 13 qtrs — |
| 49 | ABRDN PLC | 165.2K +88.5K (+115.4%) | 16.62M +10.0M (+150.5%) | 0.23% +0.122 pp | 0.03% +0.015 pp | USD88.55 +13.6% | 7 qtrs — |
| 50 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 163.4K +110.9K (+211.1%) | 16.43M +11.9M (+261.9%) | 0.23% +0.153 pp | 1.54% +1.033 pp | USD82.63 +21.7% | 13 qtrs — |
| 51 | BANK OF NEW YORK MELLON CORP | 161.6K +16.2K (+11.1%) | 16.26M +3.7M (+29.3%) | 0.22% +0.022 pp | 0.00% +0.001 pp | USD58.43 +72.2% | 18 qtrs — |
| 52 | NICHOLAS INVESTMENT PARTNERS, LP | 160.5K +36.3K (+29.2%) | 16.14M +5.4M (+50.3%) | 0.22% +0.050 pp | 1.18% +0.355 pp | USD73.36 +37.1% | 10 qtrs — |
| 53 | TD ASSET MANAGEMENT INC | 153.4K +43.8K (+39.9%) | 15.43M +5.9M (+62.8%) | 0.21% +0.060 pp | 0.01% +0.005 pp | USD89.93 +11.9% | 13 qtrs — |
| 54 | RAYMOND JAMES FINANCIAL INC | 152.0K +20.9K (+16.0%) | 15.26M +3.9M (+34.6%) | 0.21% +0.028 pp | 0.00% +0.001 pp | USD81.28 +23.8% | 5 qtrs — |
| 55 | BAKER BROS. ADVISORS LP | 143.9K +— (+0.0%) | 14.48M +2.0M (+16.3%) | 0.20% -0.001 pp | 0.08% -0.005 pp | USD76.30 +31.8% | 3 qtrs — |
| 56 | BARCLAYS PLC | 125.3K +57.2K (+84.0%) | 12.61M +5.6M (+80.9%) | 0.17% +0.079 pp | 0.00% +0.001 pp | USD88.91 +13.1% | 16 qtrs — |
| 57 | UBS ASSET MANAGEMENT AMERICAS INC | 124.6K +59.1K (+90.4%) | 12.53M +6.9M (+121.5%) | 0.17% +0.082 pp | 0.00% +0.001 pp | USD85.50 +17.6% | 13 qtrs — |
| 58 | PARKMAN HEALTHCARE PARTNERS LLC | 118.7K -1.5K (-1.2%) | 11.94M +1.5M (+14.9%) | 0.16% -0.003 pp | 1.14% +0.053 pp | USD71.96 +39.8% | 9 qtrs — |
| 59 | NUVEEN, LLC | 107.6K +16.0K (+17.4%) | 10.83M +2.9M (+36.6%) | 0.15% +0.022 pp | 0.00% +0.001 pp | USD75.76 +32.8% | 4 qtrs — |
| 60 | FISHER ASSET MANAGEMENT, LLC | 100.7K -5.7K (-5.4%) | 10.13M +926.5K (+10.1%) | 0.14% -0.009 pp | 0.00% +0.000 pp | USD70.92 +41.8% | 4 qtrs — |
| 61 | FRED ALGER MANAGEMENT, LLC | 92.0K +3.5K (+4.0%) | 9.26M +1.6M (+20.9%) | 0.13% +0.004 pp | 0.04% +0.007 pp | USD74.26 +35.5% | 15 qtrs — |
| 62 | RUSSELL INVESTMENTS GROUP, LTD. | 91.2K -1.3K (-1.4%) | 9.17M +1.2M (+14.7%) | 0.13% -0.002 pp | 0.01% +0.001 pp | USD72.78 +38.2% | 7 qtrs — |
| 63 | POINT72 ASSET MANAGEMENT, L.P. | 88.4K +88.4K (+100.0%) | 8.89M +8.9M (+100.0%) | 0.12% +0.123 pp | 0.01% +0.010 pp | USD100.59 +0.0% | 1 qtrs NEW |
| 64 | DEUTSCHE BANK AG\ | 83.0K +11.3K (+15.8%) | 8.35M +2.2M (+34.7%) | 0.12% +0.015 pp | 0.00% +0.001 pp | USD79.71 +26.2% | 18 qtrs — |
| 65 | MILLENNIUM MANAGEMENT LLC | 81.9K +81.9K (+100.0%) | 8.23M +8.2M (+100.0%) | 0.11% +0.114 pp | 0.00% +0.004 pp | USD100.59 +0.0% | 1 qtrs NEW |
| 66 | SWISS NATIONAL BANK | 78.9K +1.7K (+2.2%) | 7.94M +1.3M (+18.9%) | 0.11% +0.002 pp | 0.00% +0.001 pp | USD50.38 +99.7% | 13 qtrs — |
| 67 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 78.3K +13.8K (+21.4%) | 7.86M +2.3M (+41.1%) | 0.11% +0.019 pp | 0.01% +0.002 pp | USD77.19 +30.3% | 13 qtrs — |
| 68 | HIGHVISTA STRATEGIES LLC | 73.3K -20.0K (-21.4%) | 7.37M -696.1K (-8.6%) | 0.10% -0.028 pp | 1.90% -0.079 pp | USD71.04 +41.6% | 12 qtrs — |
| 69 | VERITION FUND MANAGEMENT LLC | 72.0K +66.3K (+1,163.0%) | 7.24M +6.8M (+1,369.0%) | 0.10% +0.092 pp | 0.03% +0.026 pp | USD99.47 +1.1% | 6 qtrs — |
| 70 | BURKEHILL GLOBAL MANAGEMENT, LP | 70.0K +70.0K (+100.0%) | 7.04M +7.0M (+100.0%) | 0.10% +0.097 pp | 0.46% +0.464 pp | USD100.59 +0.0% | 1 qtrs NEW |
| 71 | RHUMBLINE ADVISERS | 63.8K -1.4K (-2.1%) | 6.42M +781.8K (+13.9%) | 0.09% -0.002 pp | 0.01% +0.001 pp | USD46.64 +115.7% | 16 qtrs — |
| 72 | WELLS FARGO & COMPANY/MN | 62.2K +31.3K (+101.3%) | 6.25M +3.6M (+134.2%) | 0.09% +0.043 pp | 0.00% +0.001 pp | USD85.20 +18.1% | 18 qtrs — |
| 73 | SQUAREPOINT OPS LLC | 61.7K +54.3K (+731.6%) | 6.21M +5.6M (+867.3%) | 0.09% +0.075 pp | 0.01% +0.006 pp | USD98.89 +1.7% | 13 qtrs — |
| 74 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 61.1K +60.8K (+19,555.9%) | 6.15M +6.1M (+22,674.1%) | 0.08% +0.084 pp | 0.01% +0.007 pp | USD100.47 +0.1% | 3 qtrs — |
| 75 | IKARIAN CAPITAL, LLC | 59.6K +59.6K (+100.0%) | 5.99M +6.0M (+100.0%) | 0.08% +0.083 pp | 0.47% +0.468 pp | USD100.59 +0.0% | 1 qtrs NEW |
| 76 | ENSIGN PEAK ADVISORS, INC | 54.2K -10.2K (-15.8%) | 5.45M -115.3K (-2.1%) | 0.08% -0.015 pp | 0.01% +0.001 pp | USD71.37 +40.9% | 11 qtrs — |
| 77 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 46.7K +13.6K (+41.1%) | 4.70M +1.8M (+64.2%) | 0.06% +0.019 pp | 0.01% +0.003 pp | USD85.22 +18.0% | 5 qtrs — |
| 78 | VESTAL POINT CAPITAL, LP | 46.0K -1.1M (-95.8%) | 4.63M -90.5M (-95.1%) | 0.06% -1.467 pp | 0.16% -4.139 pp | USD75.29 +33.6% | 5 qtrs — |
| 79 | RAFFERTY ASSET MANAGEMENT, LLC | 45.9K -2.0K (-4.2%) | 4.62M +472.2K (+11.4%) | 0.06% -0.003 pp | 0.02% +0.003 pp | USD52.85 +90.3% | 13 qtrs — |
| 80 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 42.4K +18.6K (+78.1%) | 4.26M +2.2M (+107.1%) | 0.06% +0.026 pp | 0.01% +0.005 pp | USD92.67 +8.5% | 2 qtrs — |
| 81 | LEGAL & GENERAL GROUP PLC | 41.7K -1.6K (-3.8%) | 4.19M +446.6K (+11.9%) | 0.06% -0.003 pp | 0.00% +0.000 pp | USD54.98 +83.0% | 18 qtrs — |
| 82 | GRANAHAN INVESTMENT MANAGEMENT, LLC | 40.2K +40.2K (+100.0%) | 4.04M +4.0M (+100.0%) | 0.06% +0.056 pp | 0.17% +0.173 pp | USD100.59 +0.0% | 1 qtrs NEW |
| 83 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 38.3K +398.0 (+1.1%) | 3.85M +574.6K (+17.5%) | 0.05% +0.000 pp | 0.00% +0.001 pp | USD50.23 +100.3% | 18 qtrs — |
| 84 | NEOS INVESTMENT MANAGEMENT LLC | 37.0K +4.0K (+12.1%) | 3.72M +867.7K (+30.4%) | 0.05% +0.005 pp | 0.02% +0.000 pp | USD76.64 +31.3% | 8 qtrs — |
| 85 | TEMA ETFS LLC | 36.5K +3.5K (+10.5%) | 3.67M +812.9K (+28.5%) | 0.05% +0.005 pp | 0.28% +0.048 pp | USD76.46 +31.6% | 5 qtrs — |
| 86 | CITIGROUP INC | 35.8K +671.0 (+1.9%) | 3.60M +563.6K (+18.5%) | 0.05% +0.001 pp | 0.00% +0.000 pp | USD69.61 +44.5% | 18 qtrs — |
| 87 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 32.5K +1.6K (+5.1%) | 3.27M +599.3K (+22.4%) | 0.05% +0.002 pp | 0.00% +0.001 pp | USD80.55 +24.9% | 7 qtrs — |
| 88 | NEW YORK STATE COMMON RETIREMENT FUND | 32.5K +4.4K (+15.7%) | 3.27M +838.3K (+34.5%) | 0.05% +0.006 pp | 0.00% +0.001 pp | USD62.33 +61.4% | 17 qtrs — |
| 89 | CREATIVE PLANNING | 29.9K +7.4K (+32.9%) | 3.01M +1.1M (+54.6%) | 0.04% +0.010 pp | 0.00% +0.001 pp | USD85.17 +18.1% | 6 qtrs — |
| 90 | JUMP FINANCIAL, LLC | 28.0K +24.4K (+695.1%) | 2.81M +2.5M (+824.8%) | 0.04% +0.034 pp | 0.03% +0.031 pp | USD98.82 +1.8% | 8 qtrs — |
| 91 | METLIFE INVESTMENT MANAGEMENT, LLC | 27.6K +2.5K (+10.1%) | 2.78M +609.9K (+28.1%) | 0.04% +0.003 pp | 0.01% +0.003 pp | USD54.72 +83.8% | 18 qtrs — |
| 92 | ALYESKA INVESTMENT GROUP, L.P. | 25.5K -75.5K (-74.7%) | 2.57M -6.2M (-70.6%) | 0.04% -0.105 pp | 0.01% -0.019 pp | USD94.31 +6.7% | 6 qtrs — |
| 93 | AQR CAPITAL MANAGEMENT LLC | 25.5K -2.1K (-7.8%) | 2.57M +174.6K (+7.3%) | 0.04% -0.003 pp | 0.00% 0.000 pp | USD73.35 +37.1% | 11 qtrs — |
| 94 | STATE OF WISCONSIN INVESTMENT BOARD | 25.2K -3.4K (-11.8%) | 2.53M +62.9K (+2.5%) | 0.03% -0.005 pp | 0.01% +0.000 pp | USD54.61 +84.2% | 13 qtrs — |
| 95 | SEVEN GRAND MANAGERS, LLC | 25.0K +25.0K (+100.0%) | 2.51M +2.5M (+100.0%) | 0.03% +0.035 pp | 0.19% +0.192 pp | USD100.59 +0.0% | 1 qtrs NEW |
| 96 | MARSHALL WACE, LLP | 23.9K +23.9K (+100.0%) | 2.41M +2.4M (+100.0%) | 0.03% +0.033 pp | 0.00% +0.002 pp | USD100.59 +0.0% | 10 qtrs — |
| 97 | SEI INVESTMENTS CO | 23.2K +17.2K (+288.1%) | 2.33M +1.8M (+351.2%) | 0.03% +0.024 pp | 0.00% +0.002 pp | USD93.76 +7.3% | 11 qtrs — |
| 98 | FIRST TRUST ADVISORS LP | 22.2K +22.2K (+100.0%) | 2.23M +2.2M (+100.0%) | 0.03% +0.031 pp | 0.00% +0.002 pp | USD100.59 +0.0% | 9 qtrs — |
| 99 | TANG CAPITAL MANAGEMENT LLC | 21.9K -28.1K (-56.2%) | 2.20M -2.1M (-49.1%) | 0.03% -0.039 pp | 0.11% -0.058 pp | USD102.30 -1.7% | 6 qtrs — |
| 100 | LEGATO CAPITAL MANAGEMENT LLC | 21.7K +9.1K (+71.8%) | 2.19M +1.1M (+99.8%) | 0.03% +0.013 pp | 0.19% +0.069 pp | USD83.68 +20.2% | 10 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 105 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | ProShares - Merger ETF MRGR | 2.34% | 373.0K | 0.75% |
| 2 | Global X - Guru Index ETF GURU | 1.29% | 816.6K | 0.75% |
| 3 | Global X - S&P Biotech ETF CURE.AX | 0.93% | 333.0K | 0.45% |
| 4 | State Street SPDR S&P Biotech ETF XBI | 0.93% | 100.29M | 0.35% |
| 5 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.63% | 470.1K | 0.19% |
| 6 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.63% | 2.90M | 0.40% |
| 7 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.63% | 6.86M | 0.35% |
| 8 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.63% | 458.9K | 0.35% |
| 9 | iShares Biotechnology ETF IBB | 0.50% | 46.66M | 0.44% |
| 10 | iShares Russell 2000 Growth ETF IWO | 0.41% | 61.62M | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.35
Bearish
Ratio by volume
0.65
Neutral
Buys
11
Sells
31
Shares acquired
125.5K
Shares disposed
193.9K
Cash buys
—
Cash sales
22.00
Net activity
-68,453
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-04 | Porter James Richard | Director / Officer | M-Exempt | A | Class A Common Stock | 30,000 | 18.93 | 567.9K | 354,879 | D | ↗ |
| 2026-05-01 | Balcom Alexandra | Officer | M-Exempt | D | Stock Option (Right to Buy) | 7,159 | 1.08 | 7.7K | 131,637 | D | ↗ |
| 2026-04-30 | Miller Deborah Ann | Officer | S-Sale | D | Class A Common Stock | 4,418 | 99.13 | 438.0K | 60,716 | D | ↗ |
| 2026-04-29 | Noci Darlene | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,500 | 27.85 | 153.2K | 92,329 | D | ↗ |
| 2026-04-09 | Pelish Henry E. | Officer | M-Exempt | A | Class A Common Stock | 3,093 | 27.85 | 86.1K | 68,697 | D | ↗ |
| 2026-04-06 | Porter James Richard | Director / Officer | S-Sale | D | Class A Common Stock | 12,425 | 103.78 | 1.29M | 331,100 | D | ↗ |
| 2026-04-01 | Lane Benjamin | Officer | A-Award | A | Class A Common Stock | 9,500 | 0.00 | — | 50,368 | D | ↗ |
| 2026-04-01 | Balcom Alexandra | Officer | M-Exempt | D | Stock Option (Right to Buy) | 11,430 | 1.08 | 12.3K | 138,796 | D | ↗ |
| 2026-03-30 | Noci Darlene | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,500 | 27.85 | 153.2K | 97,829 | D | ↗ |
| 2026-03-26 | Miller Deborah Ann | Officer | S-Sale | D | Class A Common Stock | 940 | 97.50 | 91.7K | 64,194 | D | ↗ |
| 2026-03-25 | Balcom Alexandra | Officer | S-Sale | D | Class A Common Stock | 13,700 | 100.16 | 1.37M | 85,533 | D | ↗ |
| 2026-03-24 | Balcom Alexandra | Officer | M-Exempt | D | Stock Option (Right to Buy) | 11,430 | 1.08 | 12.3K | 150,226 | D | ↗ |
| 2026-03-16 | Lane Benjamin | Officer | — | — | Stock Option (Right to Buy) | 731 | 18.93 | 13.8K | 0 | D | ↗ |
| 2026-03-13 | Pelish Henry E. | Officer | S-Sale | D | Class A Common Stock | 804 | 97.89 | 78.7K | 69,904 | D | ↗ |
| 2026-03-12 | Pelish Henry E. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 8,456 | 18.93 | 160.1K | 2,113 | D | ↗ |
| 2026-03-06 | Porter James Richard | Director / Officer | M-Exempt | A | Class A Common Stock | 30,000 | 27.85 | 835.5K | 354,879 | D | ↗ |
| 2026-02-26 | Noci Darlene | Officer | S-Sale | D | Class A Common Stock | 200 | 104.25 | 20.9K | 58,117 | D | ↗ |
| 2026-02-26 | Miller Deborah Ann | Officer | S-Sale | D | Class A Common Stock | 200 | 103.96 | 20.8K | 59,634 | D | ↗ |
| 2026-01-29 | Noci Darlene | Officer | S-Sale | D | Class A Common Stock | 189 | 100.95 | 19.1K | 63,428 | D | ↗ |
| 2026-01-22 | Miller Deborah Ann | Officer | M-Exempt | D | Stock Option (Right to Buy) | 14,300 | 27.85 | 398.3K | 75,154 | D | ↗ |
| 2026-01-21 | Miller Deborah Ann | Officer | M-Exempt | D | Stock Option (Right to Buy) | 700 | 27.85 | 19.5K | 89,454 | D | ↗ |
| 2026-01-07 | Turner Christopher Durant | Officer | A-Award | A | Class A Common Stock | 17,500 | 0.00 | — | 72,630 | D | ↗ |
| 2026-01-07 | Porter James Richard | Director / Officer | A-Award | A | Class A Common Stock | 46,250 | 0.00 | — | 324,879 | D | ↗ |
| 2026-01-07 | Pelish Henry E. | Officer | A-Award | A | Stock Option (Right to Buy) | 17,500 | 106.82 | 1.87M | 17,500 | D | ↗ |
| 2026-01-07 | Noci Darlene | Officer | A-Award | A | Class A Common Stock | 17,500 | 0.00 | — | 58,117 | D | ↗ |
| 2026-01-07 | Miller Deborah Ann | Officer | A-Award | A | Stock Option (Right to Buy) | 17,500 | 106.82 | 1.87M | 17,500 | D | ↗ |
| 2026-01-07 | Balcom Alexandra | Officer | A-Award | A | Stock Option (Right to Buy) | 17,500 | 106.82 | 1.87M | 17,500 | D | ↗ |
| 2026-01-06 | Turner Christopher Durant | Officer | S-Sale | D | Class A Common Stock | 225 | 98.40 | 22.1K | 55,130 | D | ↗ |
| 2026-01-06 | Porter James Richard | Director / Officer | S-Sale | D | Class A Common Stock | 675 | 98.40 | 66.4K | 278,629 | D | ↗ |
| 2026-01-06 | Pelish Henry E. | Officer | S-Sale | D | Class A Common Stock | 1,106 | 96.75 | 107.0K | 67,446 | D | ↗ |
| 2026-01-06 | Noci Darlene | Officer | S-Sale | D | Class A Common Stock | 225 | 98.40 | 22.1K | 40,617 | D | ↗ |
| 2026-01-06 | Miller Deborah Ann | Officer | S-Sale | D | Class A Common Stock | 183 | 98.40 | 18.0K | 42,134 | D | ↗ |
| 2026-01-06 | Balcom Alexandra | Officer | S-Sale | D | Class A Common Stock | 225 | 98.40 | 22.1K | 81,733 | D | ↗ |
| 2026-01-05 | Turner Christopher Durant | Officer | S-Sale | D | Class A Common Stock | 871 | 96.06 | 83.7K | 61,676 | D | ↗ |
| 2026-01-05 | Porter James Richard | Director / Officer | S-Sale | D | Class A Common Stock | 1,337 | 98.52 | 131.7K | 288,172 | D | ↗ |
| 2026-01-05 | Pelish Henry E. | Officer | S-Sale | D | Class A Common Stock | 513 | 96.06 | 49.3K | 70,535 | D | ↗ |
| 2026-01-05 | Noci Darlene | Officer | S-Sale | D | Class A Common Stock | 317 | 98.52 | 31.2K | 43,798 | D | ↗ |
| 2026-01-05 | Miller Deborah Ann | Officer | S-Sale | D | Class A Common Stock | 897 | 96.06 | 86.2K | 48,189 | D | ↗ |
| 2026-01-05 | Balcom Alexandra | Officer | S-Sale | D | Class A Common Stock | 317 | 98.52 | 31.2K | 84,914 | D | ↗ |
| 2026-01-02 | Miller Deborah Ann | Officer | S-Sale | D | Class A Common Stock | 4,005 | 100.03 | 400.6K | 55,081 | D | ↗ |
| 2025-12-30 | Noci Darlene | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,000 | 27.85 | 111.4K | 114,329 | D | ↗ |
| 2025-12-22 | Pelish Henry E. | Officer | M-Exempt | A | Class A Common Stock | 5,085 | 1.08 | 5.5K | 71,048 | D | ↗ |
| 2025-12-22 | Balcom Alexandra | Officer | M-Exempt | D | Stock Option (Right to Buy) | 34,500 | 1.08 | 37.3K | 161,656 | D | ↗ |
| 2025-12-19 | Porter James Richard | Director / Officer | M-Exempt | A | Class A Common Stock | 57,000 | 0.65 | 37.1K | 306,062 | D | ↗ |
| 2025-12-10 | Squarer Ron | Director | A-Award | A | Stock Option (Right to Buy) | 4,418 | 105.74 | 467.2K | 4,418 | D | ↗ |
| 2025-12-08 | Balcom Alexandra | Officer | S-Sale | D | Class A Common Stock | 6,984 | 110.31 | 770.4K | 54,750 | D | ↗ |
| 2025-11-28 | Noci Darlene | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,000 | 27.85 | 111.4K | 118,329 | D | ↗ |
| 2025-11-24 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 104 | 107.70 | 11.2K | 203,218 | I | ↗ |
| 2025-11-24 | Flynn James E | Director / 10% Owner | S-Sale | D | Class A Common Stock | 371,287 | 95.45 | 35.44M | 8,299,225 | I | ↗ |
| 2025-11-18 | Balcom Alexandra | Officer | M-Exempt | D | Stock Option (Right to Buy) | 729 | 72.35 | 52.7K | 33,646 | D | ↗ |
| 2025-11-17 | Miller Deborah Ann | Officer | M-Exempt | D | Stock Option (Right to Buy) | 24,200 | 6.89 | 166.7K | 94,608 | D | ↗ |
| 2025-11-17 | Balcom Alexandra | Officer | M-Exempt | D | Stock Option (Right to Buy) | 13,125 | 72.35 | 949.6K | 34,375 | D | ↗ |
| 2025-10-30 | Noci Darlene | Officer | S-Sale | D | Class A Common Stock | 218 | 104.58 | 22.8K | 48,034 | D | ↗ |
| 2025-10-30 | Miller Deborah Ann | Officer | M-Exempt | A | Class A Common Stock | 21,800 | 6.89 | 150.2K | 70,886 | D | ↗ |
| 2025-10-28 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 32,455 | 100.27 | 3.25M | 1,383,044 | D | ↗ |
| 2025-10-27 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 14,345 | 100.23 | 1.44M | 1,415,499 | D | ↗ |
| 2025-10-20 | Miller Deborah Ann | Officer | M-Exempt | A | Class A Common Stock | 5,000 | 6.89 | 34.5K | 54,086 | D | ↗ |
| 2025-10-16 | Porter James Richard | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 27,000 | 18.93 | 511.1K | 222,400 | D | ↗ |
| 2025-10-16 | Miller Deborah Ann | Officer | S-Sale | D | Class A Common Stock | 4,900 | 92.50 | 453.3K | 49,086 | D | ↗ |
| 2025-10-15 | Pelish Henry E. | Officer | S-Sale | D | Class A Common Stock | 14,205 | 90.04 | 1.28M | 65,963 | D | ↗ |
| 2025-10-15 | Miller Deborah Ann | Officer | S-Sale | D | Class A Common Stock | 15,624 | 89.98 | 1.41M | 49,086 | D | ↗ |
| 2025-10-15 | Balcom Alexandra | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,683 | 18.93 | 31.9K | 28,979 | D | ↗ |
| 2025-10-14 | Pelish Henry E. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 825 | 29.33 | 24.2K | 14,025 | D | ↗ |
| 2025-10-14 | Balcom Alexandra | Officer | M-Exempt | D | Stock Option (Right to Buy) | 20,000 | 18.93 | 378.6K | 30,662 | D | ↗ |
| 2025-10-13 | Pelish Henry E. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,168 | 27.85 | 116.1K | 21,528 | D | ↗ |
| 2025-10-13 | Balcom Alexandra | Officer | M-Exempt | D | Stock Option (Right to Buy) | 13,125 | 18.93 | 248.5K | 50,662 | D | ↗ |
| 2025-10-01 | Balcom Alexandra | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,213 | 18.93 | 60.8K | 63,787 | D | ↗ |
| 2025-09-30 | Balcom Alexandra | Officer | M-Exempt | A | Class A Common Stock | 20,000 | 6.89 | 137.8K | 81,734 | D | ↗ |
| 2025-09-29 | Noci Darlene | Officer | M-Exempt | A | Class A Common Stock | 4,000 | 27.85 | 111.4K | 52,034 | D | ↗ |
| 2025-09-29 | Balcom Alexandra | Officer | M-Exempt | A | Class A Common Stock | 7,588 | 6.89 | 52.3K | 69,322 | D | ↗ |
| 2025-09-15 | Porter James Richard | Director / Officer | M-Exempt | A | Class A Common Stock | 27,000 | 18.93 | 511.1K | 276,062 | D | ↗ |
| 2025-09-10 | Pelish Henry E. | Officer | S-Sale | D | Class A Common Stock | 3,725 | 78.83 | 293.6K | 65,963 | D | ↗ |
| 2025-08-29 | Pelish Henry E. | Officer | M-Exempt | A | Class A Common Stock | 3,000 | 1.08 | 3.2K | 65,963 | D | ↗ |
| 2025-08-25 | Noci Darlene | Officer | S-Sale | D | Class A Common Stock | 1,348 | 73.96 | 99.7K | 50,686 | D | ↗ |
| 2025-08-15 | Porter James Richard | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 27,000 | 18.93 | 511.1K | 276,400 | D | ↗ |
| 2025-08-07 | Pelish Henry E. | Officer | S-Sale | D | Class A Common Stock | 5,500 | 74.85 | 411.7K | 60,956 | D | ↗ |
| 2025-07-30 | Noci Darlene | Officer | M-Exempt | D | Stock Option (Right to Buy) | 4,000 | 27.85 | 111.4K | 134,329 | D | ↗ |
| 2025-07-16 | Balcom Alexandra | Officer | M-Exempt | A | Class A Common Stock | 14,700 | 18.93 | 278.3K | 76,434 | D | ↗ |
| 2025-07-15 | Porter James Richard | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 27,000 | 18.93 | 511.1K | 303,400 | D | ↗ |
| 2025-07-15 | Balcom Alexandra | Officer | M-Exempt | A | Class A Common Stock | 5,300 | 18.93 | 100.3K | 67,034 | D | ↗ |
| 2025-07-10 | Pelish Henry E. | Officer | M-Exempt | A | Class A Common Stock | 182 | 18.93 | 3.4K | 61,138 | D | ↗ |
| 2025-07-09 | Pelish Henry E. | Officer | S-Sale | D | Class A Common Stock | 1,945 | 81.08 | 157.7K | 61,156 | D | ↗ |
| 2025-06-27 | Pelish Henry E. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,823 | 29.33 | 53.5K | 25,299 | D | ↗ |
| 2025-06-27 | Balcom Alexandra | Officer | S-Sale | D | Class A Common Stock | 20,000 | 80.02 | 1.60M | 61,734 | D | ↗ |
| 2025-06-26 | Noci Darlene | Officer | M-Exempt | A | Class A Common Stock | 4,000 | 27.85 | 111.4K | 52,034 | D | ↗ |
| 2025-06-25 | Pelish Henry E. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,677 | 27.85 | 102.4K | 28,675 | D | ↗ |
| 2025-06-18 | Wheeler Cameron | Director | A-Award | A | Stock Option (Right to Buy) | 4,147 | 75.53 | 313.2K | 4,147 | D | ↗ |
| 2025-06-18 | Srivastava Sapna | Director | A-Award | A | Stock Option (Right to Buy) | 4,147 | 75.53 | 313.2K | 4,147 | D | ↗ |
| 2025-06-18 | Shair Matthew | Director | A-Award | A | Class A Common Stock | 2,647 | 0.00 | — | 1,429,844 | D | ↗ |
| 2025-06-18 | Protopapas Anna | Director | A-Award | A | Stock Option (Right to Buy) | 4,147 | 75.53 | 313.2K | 4,147 | D | ↗ |
| 2025-06-18 | Pearlberg Joseph | Director | A-Award | A | Stock Option (Right to Buy) | 4,147 | 75.53 | 313.2K | 4,147 | D | ↗ |
| 2025-06-18 | Oliger Christy J. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-06-18 | Meyers Michael L. | Director | A-Award | A | Stock Option (Right to Buy) | 4,147 | 75.53 | 313.2K | 4,147 | D | ↗ |
| 2025-06-18 | Flynn James E | Director / 10% Owner | A-Award | A | Class A Common Stock | 2,647 | 0.00 | — | 2,647 | I | ↗ |
| 2025-06-18 | Bogle Grant C. | Director | A-Award | A | Stock Option (Right to Buy) | 4,147 | 75.53 | 313.2K | 4,147 | D | ↗ |
| 2025-06-16 | Porter James Richard | Director / Officer | S-Sale | D | Class A Common Stock | 11,601 | 77.26 | 896.3K | 249,262 | D | ↗ |
| 2025-06-06 | Pelish Henry E. | Officer | M-Exempt | A | Class A Common Stock | 100 | 29.33 | 2.9K | 63,301 | D | ↗ |
| 2025-05-29 | Noci Darlene | Officer | M-Exempt | D | Stock Option (Right to Buy) | 1,871 | 27.85 | 52.1K | 142,329 | D | ↗ |
| 2025-05-15 | Porter James Richard | Director / Officer | S-Sale | D | Class A Common Stock | 11,489 | 69.99 | 804.1K | 249,397 | D | ↗ |
| 2025-04-29 | Noci Darlene | Officer | M-Exempt | A | Class A Common Stock | 4,000 | 14.40 | 57.6K | 52,034 | D | ↗ |
| 2025-04-15 | Porter James Richard | Director / Officer | S-Sale | D | Class A Common Stock | 11,060 | 69.05 | 763.7K | 254,015 | D | ↗ |
| 2025-03-27 | Noci Darlene | Officer | M-Exempt | A | Class A Common Stock | 1,773 | 14.40 | 25.5K | 52,034 | D | ↗ |
| 2025-03-17 | Porter James Richard | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 27,000 | 27.85 | 752.0K | 258,780 | D | ↗ |
| 2025-03-07 | Noci Darlene | Officer | M-Exempt | A | Class A Common Stock | 4,000 | 1.08 | 4.3K | 52,034 | D | ↗ |
| 2025-03-06 | Noci Darlene | Officer | M-Exempt | A | Class A Common Stock | 8,015 | 6.89 | 55.2K | 78,034 | D | ↗ |
| 2025-02-24 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 1,382 | 78.49 | 108.5K | 216,824 | I | ↗ |
| 2025-02-18 | Porter James Richard | Director / Officer | M-Exempt | A | Class A Common Stock | 27,000 | 27.85 | 752.0K | 276,062 | D | ↗ |
| 2025-01-31 | Pelish Henry E. | Officer | M-Exempt | A | Class A Common Stock | 3,120 | 0.87 | 2.7K | 63,101 | D | ↗ |
| 2025-01-27 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 1,040 | 82.24 | 85.5K | 219,482 | I | ↗ |
| 2025-01-15 | Porter James Richard | Director / Officer | S-Sale | D | Class A Common Stock | 5,493 | 76.65 | 421.0K | 254,904 | D | ↗ |
| 2025-01-06 | Turner Christopher Durant | Officer | S-Sale | D | Class A Common Stock | 1,152 | 78.28 | 90.2K | 65,411 | D | ↗ |
| 2025-01-06 | Porter James Richard | Director / Officer | A-Award | A | Class A Common Stock | 56,250 | 0.00 | — | 266,363 | D | ↗ |
| 2025-01-06 | Pelish Henry E. | Officer | A-Award | A | Class A Common Stock | 18,750 | 0.00 | — | 62,464 | D | ↗ |
| 2025-01-06 | Noci Darlene | Officer | S-Sale | D | Class A Common Stock | 1,152 | 78.28 | 90.2K | 50,898 | D | ↗ |
| 2025-01-06 | Miller Deborah Ann | Officer | A-Award | A | Stock Option (Right to Buy) | 37,500 | 78.09 | 2.93M | 37,500 | D | ↗ |
| 2025-01-06 | Balcom Alexandra | Officer | S-Sale | D | Class A Common Stock | 2,173 | 80.54 | 175.0K | 61,734 | D | ↗ |
| 2024-12-23 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 1,409 | 83.62 | 117.8K | 221,113 | I | ↗ |
| 2024-12-19 | Porter James Richard | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 22,000 | 0.65 | 14.3K | 565,942 | D | ↗ |
| 2024-12-17 | Balcom Alexandra | Officer | M-Exempt | A | Class A Common Stock | 8,972 | 6.89 | 61.8K | 47,000 | D | ↗ |
| 2024-12-16 | Porter James Richard | Director / Officer | S-Sale | D | Class A Common Stock | 18,969 | 86.46 | 1.64M | 196,144 | D | ↗ |
| 2024-12-16 | Pelish Henry E. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,914 | 0.65 | 3.8K | 0 | D | ↗ |
| 2024-12-11 | Hack Andrew A. F. | Director | S-Sale | D | Class A Common Stock | 1,250,000 | 88.00 | 110.00M | 1,447,267 | I | ↗ |
| 2024-12-05 | Bogle Grant C. | Director | A-Award | A | Stock Option (Right to Buy) | 4,851 | 93.73 | 454.7K | 4,851 | D | ↗ |
| 2024-11-29 | Balcom Alexandra | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 27.85 | 278.5K | 84,200 | D | ↗ |
| 2024-11-25 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 992 | 96.69 | 95.9K | 222,552 | I | ↗ |
| 2024-11-15 | Porter James Richard | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 27,000 | 27.85 | 752.0K | 366,780 | D | ↗ |
| 2024-11-01 | Noci Darlene | Officer | S-Sale | D | Class A Common Stock | 2,513 | 88.79 | 223.1K | 33,800 | D | ↗ |
| 2024-10-31 | Balcom Alexandra | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 27.85 | 278.5K | 94,200 | D | ↗ |
| 2024-10-28 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 746 | 92.27 | 68.8K | 224,595 | I | ↗ |
| 2024-10-22 | Flynn James E | Director / 10% Owner | S-Sale | D | Class A Common Stock | 1,000,000 | 97.75 | 97.75M | 8,670,512 | I | ↗ |
| 2024-10-15 | Porter James Richard | Director / Officer | M-Exempt | D | Stock Option (Right to Buy) | 27,000 | 27.85 | 752.0K | 393,780 | D | ↗ |
| 2024-10-01 | Noci Darlene | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 18.93 | 94.7K | 35,800 | D | ↗ |
| 2024-09-30 | Balcom Alexandra | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 27.85 | 278.5K | 104,200 | D | ↗ |
| 2024-09-23 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 1,121 | 102.29 | 114.7K | 227,045 | I | ↗ |
| 2024-09-16 | Pelish Henry E. | Officer | S-Sale | D | Class A Common Stock | 100 | 102.80 | 10.3K | 33,300 | — | ↗ |
| 2024-09-16 | Miller Deborah Ann | Officer | S-Sale | D | Class A Common Stock | 300 | 102.00 | 30.6K | 33,300 | — | ↗ |
| 2024-09-09 | Miller Deborah Ann | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,000 | 6.89 | 20.7K | 173,608 | — | ↗ |
| 2024-09-03 | Noci Darlene | Officer | S-Sale | D | Class A Common Stock | 1,978 | 83.95 | 166.1K | 36,322 | — | ↗ |
| 2024-08-30 | Balcom Alexandra | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 27.85 | 278.5K | 114,200 | — | ↗ |
| 2024-08-26 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 797 | 83.81 | 66.8K | 229,725 | — | ↗ |
| 2024-08-23 | Pelish Henry E. | Officer | S-Sale | D | Class A Common Stock | 10,500 | 85.08 | 893.3K | 66,095 | — | ↗ |
| 2024-08-23 | Miller Deborah Ann | Officer | M-Exempt | A | Class A Common Stock | 5,000 | 18.93 | 94.7K | 38,300 | — | ↗ |
| 2024-08-23 | Conley Emily | Director | S-Sale | D | Class A Common Stock | 3,334 | 85.02 | 283.5K | 2,507 | — | ↗ |
| 2024-08-08 | Miller Deborah Ann | Officer | S-Sale | D | Class A Common Stock | 624 | 67.17 | 41.9K | 35,564 | — | ↗ |
| 2024-08-01 | Noci Darlene | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 18.93 | 94.7K | 45,800 | — | ↗ |
| 2024-07-31 | Balcom Alexandra | Officer | S-Sale | D | Class A Common Stock | 597 | 78.05 | 46.6K | 41,807 | — | ↗ |
| 2024-07-29 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 1,200 | 78.93 | 94.7K | 231,322 | — | ↗ |
| 2024-07-15 | Conley Emily | Director | S-Sale | D | Class A Common Stock | 700 | 79.43 | 55.6K | 6,807 | — | ↗ |
| 2024-07-12 | Miller Deborah Ann | Officer | M-Exempt | D | Stock Option (Right to Buy) | 6,000 | 27.85 | 167.1K | 96,154 | — | ↗ |
| 2024-07-09 | Pelish Henry E. | Officer | — | D | Stock Option (Right to Buy) | 8,085 | 1.08 | 8.7K | 0 | — | ↗ |
| 2024-07-08 | Miller Deborah Ann | Officer | M-Exempt | D | Stock Option (Right to Buy) | 3,000 | 6.89 | 20.7K | 179,608 | — | ↗ |
| 2024-07-01 | Noci Darlene | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 18.93 | 94.7K | 50,800 | — | ↗ |
| 2024-06-28 | Balcom Alexandra | Officer | S-Sale | D | Class A Common Stock | 7,565 | 75.15 | 568.5K | 35,735 | — | ↗ |
| 2024-06-24 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 634 | 79.47 | 50.4K | 233,888 | — | ↗ |
| 2024-06-14 | Conley Emily | Director | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 13.79 | 69.0K | 31,667 | — | ↗ |
| 2024-06-12 | Wheeler Cameron | Director | A-Award | A | Class A Common Stock | 2,499 | 0.00 | — | 2,499 | — | ↗ |
| 2024-06-12 | Srivastava Sapna | Director | A-Award | A | Stock Option (Right to Buy) | 3,789 | 80.03 | 303.2K | 3,789 | — | ↗ |
| 2024-06-12 | Shair Matthew | Director | A-Award | A | Class A Common Stock | 2,499 | 0.00 | — | 1,427,197 | — | ↗ |
| 2024-06-12 | Protopapas Anna | Director | A-Award | A | Stock Option (Right to Buy) | 3,789 | 80.03 | 303.2K | 3,789 | — | ↗ |
| 2024-06-12 | Pearlberg Joseph | Director | A-Award | A | Class A Common Stock | 2,499 | 0.00 | — | 2,499 | — | ↗ |
| 2024-06-12 | Meyers Michael L. | Director | A-Award | A | Class A Common Stock | 2,499 | 0.00 | — | 2,499 | — | ↗ |
| 2024-06-12 | Hack Andrew A. F. | Director | A-Award | A | Class A Common Stock | 2,499 | 0.00 | — | 2,499 | — | ↗ |
| 2024-06-12 | Gilliland Dwight Gary | Director | A-Award | A | Stock Option (Right to Buy) | 3,789 | 80.03 | 303.2K | 3,789 | — | ↗ |
| 2024-06-12 | Flynn James E | Director / 10% Owner | A-Award | A | Class A Common Stock | 2,499 | 0.00 | — | 2,499 | — | ↗ |
| 2024-06-12 | Conley Emily | Director | A-Award | A | Class A Common Stock | 2,499 | 0.00 | — | 2,507 | — | ↗ |
| 2024-06-06 | Miller Deborah Ann | Officer | S-Sale | D | Class A Common Stock | 526 | 76.88 | 40.4K | 39,638 | — | ↗ |
| 2024-05-28 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 1,256 | 66.87 | 84.0K | 235,266 | — | ↗ |
| 2024-05-15 | Conley Emily | Director | S-Sale | D | Class A Common Stock | 5,000 | 69.09 | 345.5K | 8 | — | ↗ |
| 2024-05-13 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 19,909 | 65.42 | 1.30M | 1,442,289 | — | ↗ |
| 2024-05-06 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 29,600 | 69.27 | 2.05M | 1,470,098 | — | ↗ |
| 2024-05-02 | Miller Deborah Ann | Officer | S-Sale | D | Class A Common Stock | 138 | 73.13 | 10.1K | 33,300 | — | ↗ |
| 2024-04-29 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 15,693 | 67.01 | 1.05M | 1,521,505 | — | ↗ |
| 2024-04-22 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 14,650 | 64.52 | 945.2K | 1,537,198 | — | ↗ |
| 2024-04-15 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 11,900 | 66.17 | 787.4K | 1,574,698 | — | ↗ |
| 2024-04-15 | Conley Emily | Director | S-Sale | D | Class A Common Stock | 6 | 66.66 | 399.96 | 8 | — | ↗ |
| 2024-04-08 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 11,022 | 67.89 | 748.3K | 1,638,676 | — | ↗ |
| 2024-04-04 | Miller Deborah Ann | Officer | S-Sale | D | Class A Common Stock | 731 | 71.54 | 52.3K | 35,569 | — | ↗ |
| 2024-04-01 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 27,806 | 76.82 | 2.14M | 1,659,392 | — | ↗ |
| 2024-03-28 | Miller Deborah Ann | Officer | M-Exempt | A | Class A Common Stock | 13,000 | 18.93 | 246.1K | 46,300 | — | ↗ |
| 2024-03-27 | Hack Andrew A. F. | Director | S-Sale | D | Class A Common Stock | 88,205 | 76.88 | 6.78M | 3,489,062 | — | ↗ |
| 2024-03-25 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 35,545 | 76.74 | 2.73M | 1,689,153 | — | ↗ |
| 2024-03-22 | Noci Darlene | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 1.08 | 10.8K | 36,201 | — | ↗ |
| 2024-03-15 | Conley Emily | Director | S-Sale | D | Class A Common Stock | 1,000 | 84.44 | 84.4K | 8 | — | ↗ |
| 2024-01-05 | Turner Christopher Durant | Officer | A-Award | A | Class A Common Stock | 33,300 | 0.00 | — | 47,813 | — | ↗ |
| 2024-01-05 | Porter James Richard | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 161,100 | 72.35 | 11.66M | 161,100 | — | ↗ |
| 2024-01-05 | Noci Darlene | Officer | A-Award | A | Class A Common Stock | 33,300 | 0.00 | — | 33,300 | — | ↗ |
| 2024-01-05 | Miller Deborah Ann | Officer | A-Award | A | Class A Common Stock | 33,300 | 0.00 | — | 33,300 | — | ↗ |
| 2024-01-05 | Balcom Alexandra | Officer | A-Award | A | Class A Common Stock | 33,300 | 0.00 | — | 33,300 | — | ↗ |
| 2023-12-28 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 35,056 | 75.20 | 2.64M | 1,738,190 | — | ↗ |
| 2023-12-27 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 1,000 | 75.17 | 75.2K | 1,773,246 | — | ↗ |
| 2023-12-26 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 937 | 74.22 | 69.5K | 1,842,911 | — | ↗ |
| 2023-12-19 | Miller Deborah Ann | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 18.93 | 94.7K | 102,000 | — | ↗ |
| 2023-12-18 | Protopapas Anna | Director | S-Sale | D | Class A Common Stock | 5,000 | 75.67 | 378.4K | 0 | — | ↗ |
| 2023-12-18 | Noci Darlene | Officer | M-Exempt | D | Stock Option (Right to Buy) | 22,601 | 1.08 | 24.4K | 46,201 | — | ↗ |
| 2023-12-18 | Miller Deborah Ann | Officer | S-Sale | D | Class A Common Stock | 33,046 | 75.82 | 2.51M | 0 | — | ↗ |
| 2023-12-18 | Balcom Alexandra | Officer | S-Sale | D | Class A Common Stock | 30,000 | 75.82 | 2.27M | 0 | — | ↗ |
| 2023-11-28 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 6,352 | 61.68 | 391.8K | 1,846,646 | — | ↗ |
| 2023-11-01 | Noci Darlene | Officer | S-Sale | D | Class A Common Stock | 976 | 53.11 | 51.8K | 0 | — | ↗ |
| 2023-10-24 | Shair Matthew | Director | S-Sale | D | Class A Common Stock | 81,531 | 50.63 | 4.13M | 1,863,167 | — | ↗ |
| 2023-10-04 | Turner Christopher Durant | Officer | S-Sale | D | Class A Common Stock | 1,465 | 57.70 | 84.5K | 14,513 | — | ↗ |
Executive team
Top executives
Shares Outstanding
73.54M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | James R. Porter, Ph.D. President and Chief Executive Officer | 652.1K | — | 4.39M | 5.86M | 469.5K | 21.5K | 11.39M | 89.97% | ↗ |
| 2 | 2025 | Christopher D. Turner, M.D. Chief Medical Officer | 520.1K | — | 1.46M | 1.95M | 280.9K | 21.5K | 4.24M | 80.60% | ↗ |
| 3 | 2025 | Alexandra Balcom, MBA, CPA Chief Financial Officer and Treasurer | 475.5K | — | 1.46M | 1.95M | 256.8K | 21.5K | 4.17M | 81.93% | ↗ |
| 4 | 2025 | Darlene Noci, ALM Chief Development Officer | 467.4K | — | 1.46M | 1.95M | 252.4K | 21.5K | 4.16M | 82.17% | ↗ |
| 5 | 2025 | Deborah Miller, Ph.D., J.D. Chief Legal Officer and Secretary | 467.0K | — | 1.46M | 1.95M | 252.2K | 21.5K | 4.16M | 82.18% | ↗ |
| 6 | 2024 | James R. Porter, Ph.D. President and Chief Executive Officer | 627.0K | — | 8.16M | 8.04M | 431.1K | 21.1K | 17.28M | 93.76% | ↗ |
| 7 | 2024 | Christopher D. Turner, M.D. Chief Medical Officer | 500.1K | — | 2.41M | 2.37M | 250.1K | 21.1K | 5.55M | 86.11% | ↗ |
| 8 | 2024 | Christopher Turner, M.D. Chief Medical Officer | 500.1K | — | 2.41M | 2.37M | 250.1K | 21.1K | 5.55M | 86.11% | ↗ |
| 9 | 2024 | Alexandra Balcom, MBA, CPA Chief Financial Officer and Treasurer | 457.2K | — | 2.41M | 2.37M | 228.6K | 21.1K | 5.49M | 87.12% | ↗ |
| 10 | 2024 | Deborah Miller, Ph.D., J.D. Chief Legal Officer and Secretary | 440.5K | — | 2.41M | 2.37M | 220.3K | 21.1K | 5.46M | 87.52% | ↗ |
| 11 | 2024 | Darlene Noci, ALM Chief Development Officer | 432.7K | — | 2.41M | 2.37M | 216.4K | 21.1K | 5.45M | 87.70% | ↗ |
| 12 | 2023 | James R. Porter, Ph.D. President and Chief Executive Officer | 602.8K | — | — | 8.32M | 431.0K | 20.2K | 9.38M | 88.76% | ↗ |
| 13 | 2023 | Christopher Turner, M.D. Chief Medical Officer | 480.8K | — | — | 2.85M | 250.0K | 20.2K | 3.60M | 79.16% | ↗ |
| 14 | 2023 | Christopher D. Turner, M.D. Chief Medical Officer | 480.8K | — | — | 2.85M | 250.0K | 20.2K | 3.60M | 79.16% | ↗ |
| 15 | 2023 | Alexandra Balcom, MBA, CPA Chief Financial Officer and Treasurer | 440.3K | — | — | 2.85M | 229.0K | 20.2K | 3.54M | 80.53% | ↗ |
| 16 | 2023 | Alexandra Balcom, MBA, CPA Chief Financial Officer | 440.3K | — | — | 2.85M | 229.0K | 20.2K | 3.54M | 80.53% | ↗ |
| 17 | 2022 | James Porter, Ph.D. President and Chief Executive Officer | 579.6K | — | — | 4.22M | 398.5K | 19.9K | 5.21M | 80.86% | ↗ |
| 18 | 2022 | James R. Porter, Ph.D. President and Chief Executive Officer | 579.6K | — | — | 4.22M | 398.5K | 19.9K | 5.21M | 80.86% | ↗ |
| 19 | 2022 | Christopher Turner, M.D. Chief Medical Officer | 462.3K | — | — | 1.37M | 231.2K | 20.8K | 2.08M | 65.66% | ↗ |
| 20 | 2022 | Alexandra Balcom, MBA, CPA Chief Financial Officer and Treasurer | 423.4K | — | — | 1.37M | 211.7K | 19.1K | 2.02M | 67.61% | ↗ |
| 21 | 2022 | Alexandra Balcom, MBA, CPA Chief Financial Officer | 423.4K | — | — | 1.37M | 211.7K | 19.1K | 2.02M | 67.61% | ↗ |
| 22 | 2021 | James Porter, Ph.D. President and Chief Executive Officer | 424.4K | — | — | 4.07M | 354.2K | 42.00 | 4.85M | 83.93% | ↗ |
| 23 | 2021 | Christopher Turner, M.D. Chief Medical Officer | 314.9K | — | — | 1.61M | 161.6K | 62.00 | 2.09M | 77.20% | ↗ |
| 24 | 2021 | Deborah Miller, Ph.D., J.D. Chief Legal Officer | 210.4K | — | — | 1.10M | 184.0K | — | 1.49M | 73.57% | ↗ |
| 25 | 2020 | James Porter, Ph.D. President and Chief Executive Officer | 334.6K | — | — | 306.9K | 117.3K | — | 758.7K | 40.44% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James R. Porter | Chief Executive Officer, President & Director | 1M | — |
| Christopher D. Turner | Chief Medical Officer | 822.5K | — |
| Darlene Noci | Chief Development Officer | 741.3K | female |
| Deborah Ann Miller | Chief Legal Officer & Secretary | 740.7K | female |
| Alex Balcom | Chief Financial Officer & Treasurer | 706.9K | female |
| Chelcie Lister | Senior Director of Investor Relations & Corporate Communications | — | — |
| Henry Pelish | Chief Scientific Officer | — | male |
| Benjamin Lane | Chief Technical Operations Officer | — | — |
| John Soglia | Senior Vice President of Translational Development | — | male |
| Joshua Horan | Senior Vice President of Chemistry | — | male |
| Matthew Metivier | Senior Vice President of Human Resources | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NUVL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
